Plain-English translation of NCT06937060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a weekly injectable medication, to see if it can help people who have psoriasis (a chronic skin condition) and obesity. The medication is designed to help with weight loss, and researchers believe it may also reduce inflammation and improve psoriasis symptoms. You would continue taking your regular psoriasis treatments while adding this new medication.
Doctors know that obesity makes psoriasis worse and harder to treat. Weight loss can help improve psoriasis, and this medication has shown promise for significant weight loss. However, no one has yet tested whether this specific treatment can help people with both conditions at the same time.
You likely qualify if…
You likely don't qualify if…
You would come for a screening visit, then receive weekly injections of the medication for 24 weeks while also following a reduced-calorie diet and exercise plan. The medication starts at a low dose and gradually increases. You would continue your regular psoriasis treatments as usual. After the 24-week treatment period ends, you would have follow-up visits for 12 more weeks to monitor your health and safety. The entire study lasts about 36 weeks (roughly 8–9 months).
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Hong Kong